ECSP20052897A - Inhibidores de cd73 - Google Patents

Inhibidores de cd73

Info

Publication number
ECSP20052897A
ECSP20052897A ECSENADI202052897A ECDI202052897A ECSP20052897A EC SP20052897 A ECSP20052897 A EC SP20052897A EC SENADI202052897 A ECSENADI202052897 A EC SENADI202052897A EC DI202052897 A ECDI202052897 A EC DI202052897A EC SP20052897 A ECSP20052897 A EC SP20052897A
Authority
EC
Ecuador
Prior art keywords
inhibitors
pyridazin
dione
pyrimidine
cycloalkyl
Prior art date
Application number
ECSENADI202052897A
Other languages
English (en)
Inventor
Jennifer Marie Howell
Paredes Maria Cristina Garcia
Yan Wang
Robert Dean Dally
Frank George Njoroge
Genshi Zhao
Lawrence Joseph Ii Heinz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP20052897A publication Critical patent/ECSP20052897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona 5-[5]-[2-cicloalquil]-6-piridazin-3-il]-1H-pirimidin-2,4-diona, o sales aceptables desde el punto de vista farmacéutico de este, que inhiben la actividad de CD73 y son útiles en el tratamiento contra el cáncer.
ECSENADI202052897A 2018-03-01 2020-08-31 Inhibidores de cd73 ECSP20052897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05

Publications (1)

Publication Number Publication Date
ECSP20052897A true ECSP20052897A (es) 2020-09-30

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202052897A ECSP20052897A (es) 2018-03-01 2020-08-31 Inhibidores de cd73

Country Status (33)

Country Link
US (1) US11028074B2 (es)
EP (1) EP3759096B1 (es)
JP (1) JP6794560B2 (es)
KR (1) KR20200116965A (es)
CN (1) CN111819173B (es)
AU (1) AU2019228473B2 (es)
BR (1) BR112020016066A2 (es)
CA (1) CA3092661C (es)
CL (1) CL2020002158A1 (es)
CO (1) CO2020010191A2 (es)
CR (1) CR20200376A (es)
CY (1) CY1125145T1 (es)
DK (1) DK3759096T3 (es)
DO (1) DOP2020000148A (es)
EC (1) ECSP20052897A (es)
ES (1) ES2909701T3 (es)
HR (1) HRP20220459T1 (es)
IL (1) IL277006B2 (es)
JO (1) JOP20200209A1 (es)
LT (1) LT3759096T (es)
MA (1) MA52413A (es)
MX (1) MX2020009115A (es)
PE (1) PE20210177A1 (es)
PH (1) PH12020551464A1 (es)
PL (1) PL3759096T3 (es)
PT (1) PT3759096T (es)
RS (1) RS63073B1 (es)
SG (1) SG11202008366RA (es)
SI (1) SI3759096T1 (es)
TW (1) TWI702954B (es)
UA (1) UA123890C2 (es)
WO (1) WO2019168744A1 (es)
ZA (1) ZA202004805B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502548A (zh) * 2019-08-29 2022-05-13 伊莱利利公司 Cd73抑制剂的结晶形式
US20210198239A1 (en) * 2019-12-06 2021-07-01 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
AU2021261383A1 (en) * 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
WO2021222522A1 (en) * 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2022007677A1 (zh) * 2020-07-07 2022-01-13 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
AU2021341258A1 (en) 2020-09-08 2023-04-13 Betta Pharmaceuticals Co., Ltd. CD73 inhibitor and application thereof in medicine
WO2022068929A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
CA3197340A1 (en) 2020-11-05 2022-05-12 Xuejun Zhang Cd73 inhibitor and use thereof
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CN116134029A (zh) * 2020-12-10 2023-05-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023169327A1 (zh) * 2022-03-07 2023-09-14 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024006929A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024013206A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Heterocycle compounds for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709660A2 (pt) 2006-04-03 2011-07-19 Glaxo Group Limided derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
EP1860113A1 (en) 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
FI3399984T3 (fi) * 2016-01-08 2023-11-10 Arcus Biosciences Inc Ekto-5'-nukleotidaasin modulaattoreita ja niiden käyttö
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
CL2020002158A1 (es) 2020-11-13
IL277006B (en) 2022-11-01
CR20200376A (es) 2020-10-23
WO2019168744A1 (en) 2019-09-06
EP3759096B1 (en) 2022-02-16
PT3759096T (pt) 2022-03-30
PE20210177A1 (es) 2021-01-29
IL277006B2 (en) 2023-03-01
PH12020551464A1 (en) 2021-09-01
ZA202004805B (en) 2022-01-26
EP3759096A1 (en) 2021-01-06
PL3759096T3 (pl) 2022-05-09
TWI702954B (zh) 2020-09-01
RS63073B1 (sr) 2022-04-29
LT3759096T (lt) 2022-04-11
CO2020010191A2 (es) 2020-08-31
CN111819173B (zh) 2023-06-06
TW201945002A (zh) 2019-12-01
SG11202008366RA (en) 2020-09-29
KR20200116965A (ko) 2020-10-13
DK3759096T3 (en) 2022-03-07
IL277006A (en) 2020-10-29
JP6794560B2 (ja) 2020-12-02
HRP20220459T1 (hr) 2022-05-27
CY1125145T1 (el) 2024-02-16
ES2909701T3 (es) 2022-05-10
AU2019228473A1 (en) 2020-08-20
AU2019228473B2 (en) 2021-02-25
CA3092661A1 (en) 2019-09-06
MX2020009115A (es) 2022-11-15
BR112020016066A2 (pt) 2020-12-08
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
JOP20200209A1 (ar) 2020-08-30
DOP2020000148A (es) 2020-09-15
US11028074B2 (en) 2021-06-08
CA3092661C (en) 2022-07-12
MA52413A (fr) 2021-01-06
UA123890C2 (uk) 2021-06-16
JP2020517655A (ja) 2020-06-18
CN111819173A (zh) 2020-10-23

Similar Documents

Publication Publication Date Title
ECSP20052897A (es) Inhibidores de cd73
ECSP19033052A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
ECSP19032676A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CL2018001753A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201600839)
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
WO2016198698A8 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
CO2022000270A2 (es) Inhibidores de enzimas
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2016003271A1 (es) Métodos para tratar infecciones
EA202091821A1 (ru) Ингибиторы cd73
CL2019001046A1 (es) Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131)
MA53225A (fr) Agents inhibiteurs d'ask1